Cargando…

Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo

The elimination of amyloid beta (Aβ) oligomers is a promising strategy for therapeutic drug development of Alzheimer’s disease (AD). AD mouse models that develop Aβ pathology have been used to demonstrate in vivo efficacy of compounds that later failed in clinical development. Here, we analyze the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kass, Bettina, Schemmert, Sarah, Zafiu, Christian, Pils, Marlene, Bannach, Oliver, Kutzsche, Janine, Bujnicki, Tuyen, Willbold, Dieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133466/ https://www.ncbi.nlm.nih.gov/pubmed/35584626 http://dx.doi.org/10.1016/j.xcrm.2022.100630

Ejemplares similares

Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology
por: Schemmert, Sarah, et al.
Publicado: (2018)

Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs – A model of sporadic Alzheimer’s disease
por: Kutzsche, Janine, et al.
Publicado: (2023)

Development and Implementation of an Internal Quality Control Sample to Standardize Oligomer-Based Diagnostics of Alzheimer’s Disease
por: Pils, Marlene, et al.
Publicado: (2023)

In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer’s Disease
por: Schemmert, Sarah, et al.
Publicado: (2021)

Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting
por: Blömeke, Lara, et al.
Publicado: (2022)

Patients with isolated REM-sleep behavior disorder have elevated levels of alpha-synuclein aggregates in stool
por: Schaffrath, Anja, et al.
Publicado: (2023)

The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology
por: van Groen, Thomas, et al.
Publicado: (2017)

Do We Need Anti-Prionic Compounds to Treat Alzheimer’s Disease?
por: Willbold, Dieter, et al.
Publicado: (2019)

Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay
por: Kühbach, Katja, et al.
Publicado: (2016)

Sex-Related Motor Deficits in the Tau-P301L Mouse Model
por: Camargo, Luana Cristina, et al.
Publicado: (2021)

PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer’s Disease
por: Camargo, Luana Cristina, et al.
Publicado: (2021)

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease
por: Kutzsche, Janine, et al.
Publicado: (2017)

Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination
por: Klein, Antonia Nicole, et al.
Publicado: (2016)

Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice
por: Dunkelmann, Tina, et al.
Publicado: (2018)

Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers
por: Elfgen, Anne, et al.
Publicado: (2019)

In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease
por: Schartmann, Elena, et al.
Publicado: (2018)

Oral Treatment with d-RD2RD2 Impedes Early Disease Mechanisms in SOD1*G93A Transgenic Mice but Does Not Prolong Survival
por: Wintz, Katharina, et al.
Publicado: (2023)

QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers
por: Brener, Oleksandr, et al.
Publicado: (2015)

A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model
por: Post, Julia, et al.
Publicado: (2021)

Safety and pharmacokinetics of the orally available antiprionic compound PRI‐002: A single and multiple ascending dose phase I study
por: Kutzsche, Janine, et al.
Publicado: (2020)

Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1(G93A) Transgenic Mice
por: Post, Julia, et al.
Publicado: (2021)

Aβ42 pentamers/hexamers are the smallest detectable oligomers in solution
por: Wolff, Martin, et al.
Publicado: (2017)

Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity
por: Rudolph, Stephan, et al.
Publicado: (2016)

Correction: Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity
por: Rudolph, Stephan, et al.
Publicado: (2016)

Seeded Fibrillation as Molecular Basis of the Species Barrier in Human Prion Diseases
por: Luers, Lars, et al.
Publicado: (2013)

Origin of metastable oligomers and their effects on amyloid fibril self-assembly
por: Hasecke, Filip, et al.
Publicado: (2018)

Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy
por: König, Anna S., et al.
Publicado: (2021)

Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimer’s Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography
por: Willuweit, Antje, et al.
Publicado: (2021)

In Vitro and In Vivo Neurotoxicity of Prion Protein Oligomers
por: Simoneau, Steve, et al.
Publicado: (2007)

Direct detection of alpha synuclein oligomers in vivo
por: Dimant, Hemi, et al.
Publicado: (2013)

Structural basis for the inhibition of IAPP fibril formation by the co-chaperonin prefoldin
por: Törner, Ricarda, et al.
Publicado: (2022)

Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer’s Disease and Other Tauopathies
por: Altendorf, Tim, et al.
Publicado: (2023)

Detection of Prion Protein Particles in Blood Plasma of Scrapie Infected Sheep
por: Bannach, Oliver, et al.
Publicado: (2012)

Tau protein aggregation associated with SARS-CoV-2 main protease
por: Eberle, Raphael Josef, et al.
Publicado: (2023)

In vivo neuromodulation of animal behavior with organic semiconducting oligomers
por: Tommasini, Giuseppina, et al.
Publicado: (2023)

Ex-vivo Kidney Machine Perfusion: Therapeutic Potential
por: Zulpaite, Ruta, et al.
Publicado: (2021)

Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease
por: Jiang, Nan, et al.
Publicado: (2015)

An ex vivo human aqueous humor-concentration comparison of two commercial bromfenac formulations
por: Walters, Thomas R, et al.
Publicado: (2018)

Cofilin Oligomer Formation Occurs In Vivo and Is Regulated by Cofilin Phosphorylation
por: Goyal, Pankaj, et al.
Publicado: (2013)

In vivo induction of membrane damage by β-amyloid peptide oligomers
por: Julien, Carl, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_irj3j7gtf6gs4enupjdd2fm1gk